Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03442361
Other study ID # AJCN Raman
Secondary ID
Status Completed
Phase N/A
First received January 23, 2018
Last updated February 15, 2018
Start date July 1, 2012
Est. completion date January 10, 2018

Study information

Verified date February 2018
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Intravenous lipid emulsions (IVLE) are an essential component of parenteral nutrition (PN). Omega-6 reducing strategies may improve outcomes, including reduced PN associated liver disease.

Objective: The primary objective was to compare serum alkaline phosphatase (ALP), among surgical and medical patients provided with either Intralipid or Clinoleic lipid emulsions.

Design: In this quasi-experimental study the medical records of surgical and medical adult patients were reviewed from 3 Canadian hospitals that received PN with either soybean oil (Intralipid) or predominantly olive oil (Clinoleic) based lipid emulsions for at least 7 consecutive days.


Description:

A few small studies have shown that a predominantly olive oil based IVLE is well tolerated and safe, however the clinical relevance of this IVLE is uncertain as no clear benefit in outcomes has been observed in small randomized clinical trials. Given the limited data available for the adult population reporting on the experience with olive oil based IVLE, we designed a quasi-experimental study to review our experience with Clinoleic compared to Intralipid. The primary objective was to compare the impact of Intralipid and Clinoleic IVLE on serum alkaline phosphatase (ALP), pre-PN to after one week of PN (i.e. between day 8 to 16 post-PN initiation), while controlling for the ordered lipid dosing. Secondary objectives were to assess if there were differences between the IVLEs on the remaining liver function tests, lipid dosing, incidence of infectious complications, length of stay in hospital and 30- day mortality.

This retrospective quasi-experimental chart review was conducted in 3 tertiary care hospitals in Calgary, AB between July 01, 2012 to June 30, 2013 and July 01, 2014 to June 30, 2015. Standard soybean oil-based therapy, Intralipid was the only available IVLE in Calgary, AB until July 2013, at which time predominantly olive oil Clinoleic was approved as an alternative in the hospital formulary, accounting for the dates chosen for the study. Ethics approval from the Conjoint Health Research and Ethics Board at the University of Calgary was obtained prior to the initiation of the study.


Recruitment information / eligibility

Status Completed
Enrollment 206
Est. completion date January 10, 2018
Est. primary completion date June 30, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- admitted to hospital who received PN with Intralipid or Clinoleic IVLEs for at least 7 consecutive days.

Exclusion Criteria:

- baseline liver disease

- home PN prior to admission

- ALP and total bilirubin (TB) not available within 3 days prior to PN start as well as between days 8 to 16 post PN start

- receipt of Diprivan 1%® (Propofol 116 - AstraZeneca Canada Inc., Mississauga, Canada) during PN support period

- enteral nutrition providing greater than 600 Kcal daily for longer than half of time period on PN

- oral intake of greater than 50% of hospital meal tray contents for longer than half of the PN support time period

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Outcome

Type Measure Description Time frame Safety issue
Primary Serum ALP Level Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary Serum ALT Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary Serum GGT Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary Serum TB Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary Serum BD Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary Serum TG Difference between Intralipid and Clinoleic groups 8 to 16 days after PN initiation
Secondary IVLE prescriptions dosing Difference between Intralipid and Clinoleic groups Day 3 to 16 after PN initiation
Secondary All cause mortality Difference between Intralipid and Clinoleic groups By 30 days after PN initiation
Secondary Length of hospital stay Difference between Intralipid and Clinoleic groups During PN Period
Secondary Infectious complications incidence Difference between Intralipid and Clinoleic groups During PN Period
See also
  Status Clinical Trial Phase
Completed NCT00910104 - Cholestasis Reversal: Efficacy of IV Fish Oil Phase 2/Phase 3
Recruiting NCT01157780 - Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation N/A
Completed NCT00862446 - Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease Phase 4
Completed NCT05181085 - Study of NST-6179 in Healthy Subjects Phase 1
Completed NCT02010034 - Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury N/A
Completed NCT05347888 - How Well do we Feed the Critically Ill Patients
Withdrawn NCT04807478 - Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
No longer available NCT02121769 - Omegaven Expanded Access Protocol
Approved for marketing NCT03561194 - Omegaven Protocol:Intermediate Size Patient Population